Indicated for type 2 diabetes mellitus and heart failure to manage glucose and support cardiovascular health.
Mechanism of Action
Dapagliflozin inhibits the SGLT2 transporter in the kidneys. This blocks the reabsorption of glucose into the blood, allowing excess sugar and fluid to be eliminated through the urine, effectively lowering blood glucose and cardiac load.
Route of Administration
Oral
Onset Time
1 week
Duration
24 hours
Contraindications
Severe renal impairment, Dialysis, Hypersensitivity to dapagliflozin
Information related to Farxiga is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
